BMRN BioMarin Pharmaceutical Inc.
Healthcare$52.88-2.24%ClosedMarket Cap: $10.22B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.68
P/S
3.22
EV/EBITDA
20.05
DCF Value
$10.34
FCF Yield
7.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
75.9%
Operating Margin
13.5%
Net Margin
8.3%
ROE
4.4%
ROA
3.1%
ROIC
3.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $766.2M | 74.6% | $129.6M | $105.5M | $— | — |
| Q4 null | $874.6M | 66.3% | $79.4M | $-46.6M | $— | — |
| FY null | $3.22B | 77.1% | $533.5M | $348.9M | $— | — |
| Q4 2025 | $-2.35B | 81.2% | $-454.1M | $-368.7M | $-1.88 | — |
| Q3 null | $776.1M | 82.0% | $-46.7M | $-30.7M | $— | — |
| FY 2025 | $0.00 | NaN% | $0.00 | $26.8M | $0.14 | — |
| Q2 null | $825.4M | 81.8% | $276.9M | $240.5M | $— | — |
| Q1 null | $745.1M | 79.7% | $223.9M | $185.7M | $— | — |
| Q4 null | $747.3M | 81.8% | $161.4M | $124.9M | $— | — |
| FY null | $2.85B | 79.7% | $484.2M | $426.9M | $— | — |
| Q3 null | $745.7M | 74.7% | $113.9M | $106.1M | $— | — |
| Q2 null | $712.0M | 81.7% | $120.5M | $107.2M | $— | — |